Oral surveillance e a segurança dos inibidores JAK: a teoria da relatividade

Nat Rev Rheumatol. 2022. Epub ahead of print doi: 10.1038/s41584-022-00767-7

Putting the data into context, Winthrop, et al. conclude that the ORAL Surveillance data are not dissimilar to those from the original developmental programme, which suggested additional safety concerns at the 10 mg dosage and that resulted in the 5 mg twice daily dosage as the approved dose for RA.Following the recent results of the ORAL Surveillance (ORALSURV) study, and the consequent changes to the utilisation of JAKinibs, made by the regulatory authorities, Winthrop, et al. aim to put the ORALSURV adverse events findings in the context of the JAKinib studies to date.

Keywords:


Publication thumbnail: Oral surveillance e a segurança dos inibidores JAK: a teoria da relatividade
LinkedIn